Yeasts in the Gut: from Commensals to Infectious Agents Jürgen Schulze, Ulrich Sonnenborn

Total Page:16

File Type:pdf, Size:1020Kb

Yeasts in the Gut: from Commensals to Infectious Agents Jürgen Schulze, Ulrich Sonnenborn MEDICINE REVIEW ARTICLE Yeasts in the Gut: From Commensals to Infectious Agents Jürgen Schulze, Ulrich Sonnenborn SUMMARY hree decades ago, on the basis of case reports, the American physician C. O. Truss (e1–e3) Background: Controversy still surrounds the question T proposed the hypothesis that an unhealthy lifestyle whether yeasts found in the gut are causally related to and increased intake of drugs, modified foods, and disease, constitute a health hazard, or require treatment. pollutants could lead to overgrowth of Candida Methods: The authors present the state of knowledge in this species in the intestine. This would generally reduce area on the basis of a selective review of articles retrieved the defenses of the host organism and trigger a multi- by a PubMed search from 2005 onward. The therapeutic organ Candida-associated complex of symptoms recommendations follow the current na tional and (“Candida hypersensitivity syndrome”). Since then, international guidelines. this topic has been repeatedly and vigorously dis- Results: Yeasts, mainly Candida species, are present in the cussed by experts and laymen. In 1996, C. Seebacher gut of about 70% of healthy adults. Mucocutaneous Candida even claimed that “mycophobia” was spreading. infections are due either to impaired host defenses or to Many of the publications supporting Truss’s hypoth- altered gene expression in formerly commensal strains. esis are not to be taken seriously. Abnormal condi- The expression of virulence factors enables yeasts to form tions and severe diseases have often been uncritically biofilms, destroy tissues, and escape the immunological linked to the mere detection of fungi in the gut, lead- attacks of the host. Yeast infections of the intestinal mucosa ing to the initiation of antimycotic therapy. This pro- are of uncertain clinical significance, and their possible voked justifiably critical publications during the connection to irritable bowel syndrome, while plausible, 1990s, although some of these were exaggeratedly remains unproved. Yeast colonization can trigger allergic polemical (for example, e4). An objective scientific reactions. Mucosal yeast infections are treated with discussion on intestinal Candida colonization, with topically active polyene antimycotic drugs. The adjuvant evaluation according to criteria of environmental administration of probiotics is justified on the basis of medicine, was started in 2004, under the manage- positive results from controlled clinical trials. ment of the Robert Koch Institute (1). Nevertheless, Conclusion: The eradication of intestinal yeasts is advised some questions remain open. only for certain clearly defined indications. Since then, microbiological, molecular biological, and experimental clinical studies have succeeded in Key words: gastrointestinal mycosis, candidiasis, clarifying additional facts, so that it appears to be yeast infection, pathogenesis, treatment appropriate to re-evaluate the clinical importance of yeasts in the gut. Methods The report of the Commission on Methods and Quality Assurance in Environmental Medicine (Kommission “Methoden und Qualitätssicherung in der Umwelt- medizin”) on the Pathogenetic Significance of Candida Colonization of the Intestine appeared in 2004 (1). In order to identify later relevant literature, the database PubMed was searched and evaluated from 2005. The following search terms (MeSH) were used as selection criteria in the preparation of the present review article: “Candida/pathogenicity,” “fungi/pathogenicity/viru- lence factors,” “Candida/clinical trials, humans,” Cite this as: Dtsch Arztebl Int 2009; 106(51–51): 837–42 “mycoses/microbiology/drug therapy AND gastrointes- DOI: 10.3238/arztebl.2009.0837 tinal tract OR urogenital system.” Publications on molds were not considered. Therapeutic statements are Nuthetal, Alice-Bloch-Straße: PD Dr. rer. nat. Schulze in accordance with national and international guide- Ardeypharm GmbH, Herdecke: Dr. rer. nat. Sonnenborn lines. Deutsches Ärzteblatt International | Dtsch Arztebl Int 2009; 106(51–52): 837–42 837 MEDICINE TABLE 1 gastrointestinal microflora (3, 4, 5). They are then guests which cause no damage. For example, oral and Information on microorganism groups and counts in different sections of the esophageal candidiasis is only manifest when CD4+ gastrointestinal tract Th1 lymphocytes deficiency and reduced formation of Microorganisms Stomach Jejunum Ileum Colon proinflammatory cytokines (IL-12, INF-gamma) Aerobic and facultatively anaerobic microorganism groups prevent effective defense against fungi (6, e6). Candida infections may arise as a consequence of Enterobacteria 0–102 0–103 102–106 104–1010 3 4 2 6 5 10 ● disturbances in the host’s defense systems, includ- Enterococci 0–10 0–10 10 –10 10 –10 2 3 2 5 4 7 Staphylococci 0–10 0–10 10 –10 10 –10 ing the physiological intestinal microflora, the 3 4 2 5 6 10 Lactobacilli 0–10 0–10 10 –10 10 –10 2 2 2 3 2 6 gut-associated immune system and the mucosa Fungi 0–10 0–10 10 –10 10 –10 itself (4, 5, 7, e7); Anaerobic microorganism groups ● changes in gene expression in previously Bacteroides spp. rare 0–102 103–107 1010–1012 commensal Candida strains, including activation Bifidobacteria rare 0–103 103–105 108–1012 of virulence genes (8, e7–e9). Anaerobic streptococci rare 0–103 102–104 108–1011 Clostridia rare rare 102–104 106–1011 Eubacteria rare rare rare 109–1012 Janus-headed Candida Candida spp. are yeasts which are normally present as (Essential microorganism groups compiled as in [2]. individual cells and which predominantly replicate Figures in colony forming units (CFU) per mL or per g intestinal content. asexually by budding. The expression “yeast fungus” is pleonastic, as yeasts belong to the kingdom of the fungi. Candida albicans is a diploid polymorphic yeast with eight pairs of chromosomes. It can also replicate Intestinal microflora and fungi under anaerobic conditions, as found in the human Already at birth, microbial colonization starts in the colon (e8). Almost 200 Candida species are known, gastrointestinal tract, which has previously been sterile. although few are important for man. The most impor - Intestinal microflora—now also known as microbio- tant of these are C. albicans, C. glabrata, C. krusei, C. ta—is established in successive stages and consists of dubliniensis, C. tropicalis, C. parapsilosis, C. guillier- numerous types of microorganism. More than 99% of mondii, and C. lusitaniae (3, 4, e10). One reason that this microbiota consists of bacterial and archaeal this list is short is that about two thirds of Candida species (2). In addition, Candida yeasts are detectable species are incapable of growing at 37oC (e10). in 96% of neonates by the end of the first month of life Molecular genetic studies have shown that there is (e5). The constitutional development process is much greater variety in individual Candida flora (e11). complete after 3 to 5 years and each individual then has Candida yeasts are classified as opportunistic an individual microflora compatible with his/her pathogens, meaning that they are pathogens only under immune system. The special anatomical and physio- specific conditions (4, e7). Overgrowth of yeasts is logical features of the individual compartments of the normally inhibited by both specific (immune system) mouth, stomach and intestine offer disparate ecological and non-specific defense systems (intestinal flora, niches and they are colonized with site-specific peristalsis, intestinal enzymes, defensins, and others). microbe communities (2). Changes in the qualitative or quantitative composi- Table 1 contains groups of important microorgan- tion of the bacterial flora in the gastrointestinal isms detected by culture. The concentration ranges tract—for example, after administration of antibiotics given for the individual counts of life microbes indicate (9)—or a deficiency in specific parameters of the host’s the great individual variability in the microflora of immune system evidently enhance the virulence of adults. The findings also show that fungi are detectable opportunistic Candida strains through gene regulation in all gastrointestinal sections of about 70% of healthy mechanisms (10, e7, e12). Their damaging activities adults (1). Most of these are members of the Candida can manifest at two different levels: genus. Normally 101 to 103 fungal cells per g stool are ● Superficial infections of the skin, mucus found, which is much lower than the corresponding membranes, or epithelia (skin or mucosal values for bacteria – 1011 to 1012 bacteria per g stool. mycoses, Candida vaginoses) Fungi of other genera are occasionally detected in ● Invasive penetration into deeper tissue layers, stool. Although these may be pathogens of the respi - distribution in blood and dissemination in various ratory tract or skin, they are thought to be only transient organs (invasive or systemic mycoses or candi- in the digestive tract. Examples include Aspergillus, doses). Mucor, Cryptococcus, Rhodotorula, and Trichosporon. Even though Candida species are relatively often Pathogenicity factors of Candida strains detected in stool, it is unclear whether these fungi are Pathogenic yeasts bear genes coding for specific patho- physiological and (useful) intestinal symbionts. As long genicity factors and for other properties important for as the site-specific microbial communities are intact the infection process (10, 11, e7). These primarily and the innate immune system is functioning, Candida include adhesion factors,
Recommended publications
  • Systemic Antifungal Drug Use in Belgium—
    Received: 7 October 2018 | Revised: 28 March 2019 | Accepted: 14 March 2019 DOI: 10.1111/myc.12912 ORIGINAL ARTICLE Systemic antifungal drug use in Belgium—One of the biggest antifungal consumers in Europe Berdieke Goemaere1 | Katrien Lagrou2,3* | Isabel Spriet4,5 | Marijke Hendrickx1 | Eline Vandael6 | Pierre Becker1 | Boudewijn Catry6,7 1BCCM/IHEM Fungal Collection, Service of Mycology and Aerobiology, Sciensano, Summary Brussels, Belgium Background: Reports on the consumption of systemic antifungal drugs on a national 2 Department of Microbiology and level are scarce although of high interest to compare trends and the associated epi- Immunology, KU Leuven, Leuven, Belgium 3Clinical Department of Laboratory demiology in other countries and to assess the need for antifungal stewardship Medicine, National Reference Centre for programmes. Mycosis, University Hospitals Leuven, Leuven, Belgium Objectives: To estimate patterns of Belgian inpatient and outpatient antifungal use 4Department of Pharmaceutical and and provide reference data for other countries. Pharmacological Sciences, KU Leuven, Methods: Consumption records of antifungals were collected in Belgian hospitals Leuven, Belgium between 2003 and 2016. Primary healthcare data were available for the azoles for 5Pharmacy Department, University Hospitals Leuven, Leuven, Belgium the period 2010-2016. 6 Healthcare‐Associated Infections and Results: The majority of the antifungal consumption resulted from prescriptions of Antimicrobial Resistance, Sciensano, Brussels, Belgium fluconazole and itraconazole in the ambulatory care while hospitals were responsible 7Faculty of Medicine, Université Libre de for only 6.4% of the total national consumption and echinocandin use was limited. Bruxelles (ULB), Brussels, Belgium The annual average antifungal consumption in hospitals decreased significantly by Correspondence nearly 25% between 2003 and 2016, due to a decrease solely in non-university hos- Berdieke Goemaere, Sciensano, Mycology pitals.
    [Show full text]
  • A Handbook for Practicing the Original Reiki of Usui and Hay Pdf, Epub, Ebook
    LIGHT ON THE ORIGINS OF REIKI: A HANDBOOK FOR PRACTICING THE ORIGINAL REIKI OF USUI AND HAY PDF, EPUB, EBOOK Tadao Yamaguchi | 195 pages | 01 Jan 2008 | LOTUS PRESS | 9780914955658 | English | Wisconsin, United States Light on the Origins of Reiki: A Handbook for Practicing the Original Reiki of Usui and Hay PDF Book Transcriptions Revised Romanization yeonggi. Read an excerpt of this book! Parapsychology Death and culture Parapsychology Scientific literacy. Adrenal fatigue Aerotoxic syndrome Candida hypersensitivity Chronic Lyme disease Electromagnetic hypersensitivity Heavy legs Leaky gut syndrome Multiple chemical sensitivity Wilson's temperature syndrome. Learn the basics, get attuned, and develop a solid self-care and meditation practice. Reiki is a Spiritual Discipline. Melissa Fotheringham rated it it was amazing Feb 10, Invest in Yourself. Four Faces is an adventurous survey of a universe that is deeper than science can measure. Learn how to enable JavaScript on your browser. Reiki is a powerful healing energy. Level I and II required. None of these have any counterpart in the physical world. None of the studies in the review provided a rationale for the treatment duration and no study reported adverse effects. More filters. Jack Tips. By spreading the course over 8 or more lessons, you get the time to incorporate the Reiki energy into daily life. Members for A. Master Level. Pseudoscientific healing technique. To see what your friends thought of this book, please sign up. The existence of qi has not been established by medical research. Kathia Munoz rated it really liked it Jan 28, You can learn Reiki so that you can become a conduit for helping others, or you can learn it for your own spiritual development.
    [Show full text]
  • IJP: Drugs and Drug Resistance 8 (2018) 246–264
    IJP: Drugs and Drug Resistance 8 (2018) 246–264 Contents lists available at ScienceDirect IJP: Drugs and Drug Resistance journal homepage: www.elsevier.com/locate/ijpddr Genomic and transcriptomic alterations in Leishmania donovani lines T experimentally resistant to antileishmanial drugs Alberto Rastrojoa,1, Raquel García-Hernándezb,1, Paola Vargasb, Esther Camachoa, Laura Corvoa, Hideo Imamurac, Jean-Claude Dujardinc, Santiago Castanysb, Begoña Aguadoa, ∗∗ ∗ Francisco Gamarrob, , Jose M. Requenaa, a Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Universidad Autónoma de Madrid, Madrid, Spain b Instituto de Parasitología y Biomedicina ‘‘López-Neyra’’ (IPBLN-CSIC), Granada, Spain c Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium ARTICLE INFO ABSTRACT Keywords: Leishmaniasis is a serious medical issue in many countries around the World, but it remains largely neglected in Leishmania donovani terms of research investment for developing new control and treatment measures. No vaccines exist for human Genome use, and the chemotherapeutic agents currently used are scanty. Furthermore, for some drugs, resistance and Transcriptome treatment failure are increasing to alarming levels. The aim of this work was to identify genomic and tran- Trivalent antimony criptomic alterations associated with experimental resistance against the common drugs used against VL: tri- Amphotericin B valent antimony (SbIII, S line), amphotericin B (AmB, A line), miltefosine (MIL, M line) and paromomycin (PMM, Miltefosine ff fi Paromomycin P line). A total of 1006 di erentially expressed transcripts were identi ed in the S line, 379 in the A line, 146 in 24-Sterol methyltransferase the M line, and 129 in the P line. Also, changes in ploidy of chromosomes and amplification/deletion of par- D-lactate dehydrogenase ticular regions were observed in the resistant lines regarding the parental one.
    [Show full text]
  • Nystatin and Triamcinolone Acetonide Cream, USP Nystatin And
    FRONT BACK Nystatin and Triamcinolone Acetonide Cream, USP PK-1111-3 corticosteroids. 45 Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to Nystatin and Triamcinolone Acetonide Ointment, USP systemic toxicity (see PRECAUTIONS, Pediatric Use). Rx only If irritation or hypersensitivity develops with the combination nystatin and triamcinolone acetonide, treatment should be discontinued and appropriate therapy instituted. FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE Information for the Patient: Patients using this medication should receive the following information and DESCRIPTION: Nystatin and Triamcinolone Acetonide Cream and Ointment for dermatologic use contain the instructions: antifungal agent nystatin and the synthetic corticosteroid triamcinolone acetonide. 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. Nystatin is a polyene antimycotic obtained from Streptomyces noursei. It is a yellow to light tan powder with a 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. cereallike odor, very slightly soluble in water, and slightly to sparingly soluble in alcohol. Structural formula: 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occluded (see CH3 DOSAGE AND ADMINISTRATION). O H CH3 4. Patients should report any signs of local adverse reactions. O H HO OH H2N 5. When using this medication in the inguinal area, patients should be advised to apply the cream or ointment OH OH sparingly and to wear loose fitting clothing. CH3 H H H3C 6. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being OH O COOH treated in the diaper area, as these garments may constitute occlusive dressings.
    [Show full text]
  • WO 2017/009265 Al 19 January 2017 (19.01.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/009265 Al 19 January 2017 (19.01.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A01N 31/06 (2006.01) A01N 37/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A0 37/00 (2006.01) A01P 1/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A0 37/02 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/EP2016/066368 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 8 July 2016 (08.07.2016) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 15 12 135.3 10 July 2015 (10.07.2015) GB GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: IPABC LTD [GB/GB]; The Die-Pat Centre, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Broad March, Broad March, Daventry, Northamptonshire DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, NN1 1 4HE (GB).
    [Show full text]
  • Testing the Rational of Candida Cleanse Diets
    TESTING THE RATIONAL OF CANDIDA CLEANSE DIETS A thesis presented to the faculty of the Graduate School of Western Carolina University in partial fulfillment of the requirements for the degree of Master of Science in Biology. By Sallie Katherine Lewis Director: Dr. Greg Adkison Biology Instructor Biology Department Committee Members: Dr. Sean O’Connell, Biology Dr. Sabine Rundle, Biology July 2014 ACKNOWLEDGEMENTS I would like to thank my committee members and director for their assistance and encouragement; in particular, Dr. Greg Adkison for his incredible patience, Dr. Sabine Rundle for her constant reassurance, and Dr. Sean O’Connell for his kindness and consideration. In addition, I would like to recognize J Ryan Simmons for the time he spent proofreading and editing this document. I also extend my sincere thanks to my husband Eric Sheasby for his motivation and support. And lastly, I offer my deepest thanks to my family; my husband Eric Sheasby and my parents Mike and Sherrill Lewis. Thank you for always being my biggest cheerleaders. Without the support of all of the above mentioned people this thesis would not have been possible. TABLE OF CONTENTS Page List of Figures .................................................................................................................... iv Abstract ................................................................................................................................v Introduction ..........................................................................................................................1
    [Show full text]
  • Chemical Exposures: Low Levels and High Stakes, Second Edition
    Chemical Exposures Chemical Exposures Low Levels and High Stakes Second Edition Nicholas A. Ashford Claudia S. Miller JOHN WILEY & SONS, INC. NewYork • Chichester • Weinheim • Brisbane • Singapore • Toronto This text is printed on acid-free paper. Copyright © 1998 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. No part ofthis publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except as permitted under Sections 107 and 108 ofthe 1976 United States Copyright Act, without either the prior written permission ofthe Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4744. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012. (212) 850-6011, fax (212) 850-6008, E-mail: [email protected]. Library ofCongress Cataloging-in-Publication Data Ashford, Nicholas Askounes. Chemical exposures: low levels and high stakes / Nicholas A. Ashford & Claudia S. Miller - 2nd ed. p. em. Includes bibliographical references and indexes. ISBN 0-471-29240-0 I. Multiple chemical sensitivity. I. Miller, Claudia. II. Title. RB I52.6.A84 1997 615.9'02-dc21 97-19690 CIP 10 9 8 7 6 5 4 3 To my mother, Venette Askounes Ashford, from whom I learned to have compassion for those less fartunate than I, and who inspired me to help. -N.A.A. To my parents, Constance Lawrence Schultz.
    [Show full text]
  • BCMJ -#51Vol6-July-09-July.Qxp
    personal view limiting consumption of albacore 2 Letters for Personal View are welcomed. tuna. HealthLink BC and Health They should be double-spaced and few er Canada have set different serving than 300 words. The BCMJ reserves the limits and age categories in their fish right to edit letters for clarity and length. consumption recommendations. The Letters may be e-mailed (journal@bcma recommendations also differ some- .bc.ca), faxed (604 638-2917), or sent what from those of the State of through the post. Washington and the US FDA/EPA.3 One of my associates, Dr Laurie Chan, chair of Aboriginal environ- mental health at UNBC, has told me Flu protection for the accompanying document for “In - that cheaper light tuna tends to have fection Control Guidelines in Acute an Hg level 5 times lower than that physicians Care Facilities,” www.phac-aspc.gc found in albacore tuna.4 have recently moved from Ontario .ca/alert-alerte/swine-porcine/ I would sincerely like to know the to BC in rural family practice. I guidance-orientation-ipc-eng.php. background, rationale, and references Iwork in the clinic and hospital The BC Ministry of Health Ser- used by the Ministry of Health and the full-time in Invermere, BC. vices is not planning at this time to CDC to make this recommendation. I In Ontario every doctor’s office follow the Ontario decision to supply remember listening to Ray Copes in a was supplied with a stock of protective physicians’ private offices with pro- meeting one day, and he mentioned masks, gowns, etc., after the deaths of tective equipment as the ministry Continued on page 240 doctors, nurses, and paramedics in the believes it is properly the responsibil- SARS outbreak in Ontario.
    [Show full text]
  • Amphotericin B Amphocil
    Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Amphotericin B Amphocil Abelcet DE/W/009/pdWS/001 Rapporteur: Germany Finalisation procedure (day 120): 24.11.2017 Amphotericin B DE/W/009/pdWS/001 Seite 1 TABLE OF CONTENTS I. Executive Summary ....................................................................................................... 4 II. RecommendatioN .......................................................................................................... 4 III. INTRODUCTION ............................................................................................................. 6 IV. SCIENTIFIC DISCUSSION .............................................................................................. 7 IV.1 Information on the pharmaceutical formulation used in the clinical studies .............. 7 IV.2 Non-clinical aspects ................................................................................................................... 9 IV.3 Clinical aspects .......................................................................................................................... 10 V. MEMBER STATES Overall Conclusion AND RECOMMENDATION ........................... 31 VI. List of Medicinal products and marketing authorisation holders involved ............. 33 Amphotericin B DE/W/009/pdWS/001 Page 2/33 ADMINISTRATIVE INFORMATION Invented name of the medicinal See section VI product(s): INN (or common name) of the active Amphotericin B substance(s):
    [Show full text]
  • Reset the Yeast Connection
    RESET THE YEAST CONNECTION Carolyn F. A. Dean MD ND Ver 2 ReSet The Yeast Connection www.RnAReSet.com TABLE OF CONTENTS INTRODUCTION Preview of Yeast ReSet Protocol SECTION ONE: ALL ABOUT YEAST Chapter One: The Personal Side of Yeast Chapter Two: Candida and its Toxic Friends Chapter Three: Show Me the Evidence Chapter Four: Making the Diagnosis SECTION TWO: YEAST BALANCE PROGRAM Chapter Five: Yeast ReSet Diet Chapter Six: Yeast ReSet Protocols Chapter Seven: Living a Yeast-Free Life SECTION THREE: TREATING CHILDREN, WOMEN AND MEN Chapter Eight: Children With Yeast Chapter Nine: Women With Yeast Chapter Ten: Men With Yeast SECTION FOUR: YEAST RESET MENU & RECIPES Chapter Eleven: Menu & Yeast ReSet Recipes REFERENCES MEET THE DOCTOR OF THE FUTURE Carolyn Dean MD ND 2 ReSet The Yeast Connection www.RnAReSet.com INTRODUCTION I’ve been studying health since my teens, and over the past five decades I’ve developed a very wide overview and perspective on our current health care crisis. Speaking with thousands of patients, clients, and callers on my radio show, I’ve identified two clear causes of most health problems. They are Mineral Deficiency and Yeast Overgrowth Syndrome (YOS) – and most people suffer from both. Candidiasis, Candida Related Complex, Candida Hypersensitivity, and Yeast Allergies are all names for what I call Yeast Overgrowth Syndrome, which I will shorten to YOS throughout the book. It’s a condition where yeast has overgrown and outgrown its natural environment in the large intestine and has invaded the small intestine. It is a health threat that remains untreated, mistreated, and if it’s ever recognized, it is undertreated.
    [Show full text]
  • Adaptation of Aspergillus Niger to Multiple Agents Whose Action Mechanisms Are Different
    Jpn. J. Med. Mycol. Vol. 36, 19-24, 1995 ISSN 0916-4804 Original Article Adaptation of Aspergillus niger to Multiple Agents Whose Action Mechanisms are Different Hideaki Matsuoka1, Jong-Chul Park1, Yasuyuki Nemoto1, Satoru Yamada2, Weimin Jing3, Yuansong Chen3, Kosuke Takatori4, Hiroshi Kurata5 1Department of Biotechnology, Faculty of Technology, Tokyo University of Agriculture and Technology, 2-24-16, Nakamachi, Koganei, Tokyo 184, Japan 2Research and Development Division, Bio-Liken Inc., 1-5-8, Iwamotocho, Chiyoda-ku, Tokyo 101, Japan 3Research and Development Division, Hidan Co. Ltd., 627, Hananoi, Kashiwa, Chiba 277, Japan 4Hatano Research Institute, Food & Drug Safety Center, 729-5, Ochiai, Hadano, Kanagawa 257, Japan 5The Tokyo Kembikyoin Foundation, 4-8-32, Kudanminami, Chiyoda-ku, Tokyo 102, Japan (Received: 9, August 1994. Accepted: 9, September 1994] Abstract Adaptation of Aspergillus niger to amphotericin B (AMPH) and two imidazoles (miconazole (MCZ) and ketoconazole (KCZ)) was observed at a single hypha level with a continuous measurement system. It was found that a test hypha adapted to MCZ or KCZ was also adapted to AMPH but that a hypha adapted to AMPH was not adapted either to MCZ or KCZ. These adaptation phenomena to respective agents did not occur after incubation in the medium supplemented with ergosterol. The cross adaptation phenomena were suspected to be due to modification of the synthesis pathway of ergosterol and related derivatives. Key words: adaptation, hyphal growth rate, Aspergillus niger, amphotericin B, miconazole, ketoconazole. rienced by many mycologists and microbiologists Introduction 5-9). The newly developed BCT system has dem- A single hypha-based microbioassay has recently onstrated those adaptation phenomena much more been proposed and applied to the evaluation of clearly by tracing the same hypha throughout.
    [Show full text]
  • Nystatin Cream USP, 100,000 Units Per Gram Rx Only
    NYSTATIN- nystatin cream Rebel Distributors Corp ---------- Nystatin Cream USP, 100,000 units per gram Rx only DESCRIPTION Nystatin Cream is for dermatologic use. Nystatin is a polyene antimycotic obtained from Streptomyces noursei. It is a yellow to light tan powder with a cereal-like odor, very soluble in water, and slightly to sparingly soluble in alcohol. Structural formula: Nystatin Cream contains the antifungal antibiotic nystatin at a concentration of 100,000 USP Nystatin Units per gram in an aqueous, perfumed cream base containing purified water, propylene glycol, methylparaben, propylparaben, white petrolatum, glyceryl monostearate, polyethylene glycol 400 monostearate, ceteareth-15, medical antifoam AF emulsion, aluminum hydroxide gel, titanium dioxide, sorbitol solution, and, if necessary, sodium hydroxide for pH adjustment. CLINICAL PHARMACOLOGY Nystatin is an antifungal antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. It probably acts by binding to sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin is the first well tolerated antifungal antibiotic of dependable efficacy for the treatment of cutaneous, oral and intestinal infections caused by Candida (Monilia) albicans and other Candida species. It exhibits no appreciable activity against bacteria. Nystatin provides specific therapy for all localized forms of candidiasis. Symptomatic relief is rapid, often occurring within 24 to 72 hours after the initiation of treatment. Cure is effected both clinically and mycologically in most cases of localized candidiasis. INDICATIONS AND USAGE Nystatin Cream is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida (Monilia) albicans and other Candida species.
    [Show full text]